Status:
COMPLETED
Reproducibility and Repeatability of Multifunctional MRI Biomarkers of the Body
Lead Sponsor:
Asan Medical Center
Collaborating Sponsors:
Bracco Diagnostics, Inc
Conditions:
Metastatic Liver Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Advanced MRI (Magnetic Resonance Imaging) technique called DCE (Dynamic Contrast Enhanced) and DWI MRI can provide valuable information regarding tumor biology and response to treatment through variou...
Eligibility Criteria
Inclusion
- Diagnosis of metastatic liver cancer proven by pathology
- At least one liver tumor should be \> 2cm in long diameter
- Patients with viable tumor proven in the other imaging modalities
Exclusion
- Severe claustrophobia
- Presence of MRI-incompatible metallic objects or implanted medical devices in body
- Renal failure, as determined by glomerular filtration rate (GFR) \< 30 mL/min/1.73 m2
- Weight greater than that allowable by the MRI table
- Chemotherapy within 28 days prior to enrollment
- Prior external radiation therapy to the liver, prior transarterial chemoembolization
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2015
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT02201797
Start Date
October 1 2014
End Date
June 1 2015
Last Update
June 24 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea, 138-736